Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
Conditions: Adenocarcinoma of the Pancreas; Adenocarcinoma of the Stomach; BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Ovarian Mucinous Cystadenocarcinoma; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Gastric Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Pancreatic Cancer; Recurrent Rectal Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Stage IV Colon Cancer; Stage IV Gastric Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Pancreatic Cancer; Stage IV Rectal Cancer; Unspecified Adult Solid Tumor, Protocol SpecificInterventions: Drug: veliparib; Drug: capecitabine; Drug: oxaliplatin; Other: pharmacological study; Other: laboratory biomarker analysisSponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)Recruiting - verified December 2012
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Eloxatin | Gastric (Stomach) Cancer | Gastroenterology | Mucinous Ovarian Cancer | Pancreas | Pancreatic Cancer | Research | Study